Citations

Mayo Clinic

Clear

708 citation(s) found for "Wu, Derek".

Quality of life analysis of NCCTG N0877 (Alliance): Phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM).
Qin, Rui , Tan, Angelina D., Sloan, Jeff A. , Lesser, Glenn J. , Anderson, S. Keith , Johnson, Derek R. , Laack, Nadia N.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e17715-e17715

10.1200/jco.2015.33.15_suppl.e17715 Get It

Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Becerra, Carlos, Stephenson, Joe , Jonker, Derek J. , Cohn, Allen Lee, Asmis, Timothy R., Conkling, Paul , Garbo, Lawrence, Lenz, Heinz‐Josef , Richards, Donald , Mikhail, Sameh , Goodwin, Rachel , Yoon, Harry H. , Hume, Stephanie , Hitron, Matthew, Li, Chiang, Bekaii‐Saab, Tanios , Spira, Alexander I.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4069-4069

10.1200/jco.2015.33.15_suppl.4069 Get It

Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance).
Anderson, S. Keith , Leinweber, Clinton, Buckner, Jan C. , Geoffroy, Francois J., Lesser, Glenn J. , Jaeckle, Kurt A. , Laack, Nadia N. , Galanis, Evanthia , Giannini, Caterina , Johnson, Derek R. , Sarkaria, Jann N.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2013-2013

10.1200/jco.2015.33.15_suppl.2013 Get It

Effect of Trinucleotide Repeat Expansion on the Expression ofTCF4mRNA in Fuchs' Endothelial Corneal Dystrophy
Okumura, Naoki , Hayashi, Ryosuke , Nakano, Masakazu , Yoshii, Kengo, Tashiro, Kei, Blake, Derek J. , Aleff, Ross A., Butz, Malinda L., Highsmith, Edward W., Wieben, Eric D. , Fautsch, Michael P. , Baratz, Keith H. , Komori, Yuya, Nakahara, Makiko , Tourtas, Theofilos , Schlötzer‐Schrehardt, Ursula , Kruse, Friedrich E., Koizumi, Noriko , Aleff, Ross, Butz, Malinda, Hayashi, Ryosuke, Sato, Takahiko

Investigative Opthalmology & Visual Science | February 27, 2019 | Volume: 60 | Issue: 2 | Pages: 779

10.1167/iovs.18-25760 | PMID 30811544 Get It

Spatial and temporal changes of midface in Apert’s syndrome
Lu, Xiaona , Forte, Antonio J. , Sawh‐Martinez, Rajendra , Wu, Robin T. , Cabrejo, Raysa, Wilson, Alexander T. , Steinbacher, Derek M., Alperovich, Michael , Alonso, Nivaldo , Persing, John A. , Forte, Antonio Jorge

Journal of Plastic Surgery and Hand Surgery | February 20, 2019 | Volume: 53 | Issue: 3 | Pages: 130-137

10.1080/2000656x.2018.1541324 | PMID 30782083 Get It

An unusual presentation of late-onset Alexander’s disease with slow orthostatic tremor and a novel GFAP variant
Stitt, Derek , Gavrilova, Ralitza H. , Watson, Robert E. , Hassan, Anhar , Stitt, Derek W, Watson, Robert

Neurocase | February 13, 2019 | Volume: 24 | Issue: 5-6 | Pages: 266-268

10.1080/13554794.2019.1580749 | PMID 30755139 Get It

Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance
Bobade, Rohit A., Helmers, Richard A. , Jaeger, Thomas M. , Odell, Laura J., Haas, Derek A. , Kaplan, Robert S.

Journal of Medical Economics | February 12, 2019 | Volume: 22 | Issue: 5 | Pages: 471-477

10.1080/13696998.2019.1582058 | PMID 30744455 Get It

Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs).
Hall, Michael J. , Bodor, J. Nicholas , Xiu, Joanne , Goldberg, Richard M. , Worrilow, William M. , Hwang, Jimmy J., Kim, Edward S. , Lenz, Heinz‐Josef , Shields, Anthony F. , Salem, Mohamed E. , Feldman, Rebecca A. , Grothey, Axel , Raghavan, Derek , Marshall, John L , Korn, Wolfgang Michael

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 505-505

10.1200/jco.2019.37.4_suppl.505 Get It

505 Background: MSI is a tumor biomarker for immunotherapy efficacy that is closely associated w/deficient MMR, and is also variably associated w/somatic muts of the MMR genes, loss of MMR protein expression by immunohistochemistry (IHC), and high TMB. Germ-line muts (Lynch syndrome/LS) in the 4 MMR genes are recognized to have distinct cancer spectrums/penetrance in LS, yet across all tumors, gene-specific variability in MMR IHC, MMR muts, and TMB is understudied. Methods: Results of TGPs performed by Caris Lifesciences (2015-17) were analyzed in colorectal (CRC), endometrial (EC) and all other cancers/tumors (OT) as: 1) all MSI-H tumors (n = 1057) and 2) all tumors w/ ≥1 mut in an MMR gene (n = 470). A subset of cases had IHC for MMR protein and PD-L1 expression. MSI and TMB were determined by NGS. Results: Characteristics of MSI-H tumors and tumors w/ ≥1 MMR mut are seen in the Table. A single MSH6 mut [F1088fs] in a coding microsatellite represented 31% of all MMR muts detected. F1088fs was found in 58% tumors w/MLH1/PMS2 loss (IHC) but only 25% w/MSH2/MSH6 loss (p < 0.001), was more commonly seen in EC vs CRC/OT (p < 0.001), and was negatively associated w/somatic POLE mut (p = 0.002). Distinct mut signatures in the MMR genes (e.g. GLUàSTOP) were seen in tumors w/POLE muts and DNA repair genes. Conclusions: MSI-H and MMR mutated tumors demonstrate marked gene-specific heterogeneity in IHC patterns, TMBs, and somatic muts that may be relevant to treatment selection, resistance, and response. [Table: see text]
Analysis of Airway and Midface in Crouzon Syndromes
Forte, Antonio J. , Lu, Xiaona , Hashim, Peter W. , Steinbacher, Derek M., Alperovich, Michael , Persing, John A. , Alonso, Nivaldo , Forte, Antonio Jorge

Annals of Plastic Surgery | January 16, 2019 | Volume: 82 | Issue: 6 | Pages: 686-691

10.1097/sap.0000000000001740 | PMID 30633021 Get It

Background Crouzon syndrome is associated with severe respiratory impairment of the upper airway due in part to midfacial dysmorphology. We calculated the distinctive nasal diameter and pharyngeal airway volume in patients with Crouzon syndrome and compared them with age-matched control subjects. Methods Children with computed tomography scans in the absence of surgical intervention were included. Computed tomography scans were digitized and manipulated using Surgicase CMF (Materialise). Craniometric data relating to the midface and airway were collected. For all linear measurements, mean percent increases or decreases were calculated relative to the size of control subjects, and volumetric assessment of the airway was tabulated. Statistical analysis was performed using t test. Results Twenty-six computed tomography scans were included (control n = 17, Crouzon n = 9). All children were in early mixed dentition. Pharyngeal airway volume was decreased in patients with Crouzon syndrome relative to control subjects by 46% (P = 0.003). The distance from the posterior tongue to the posterior pharyngeal wall decreased 31% when comparing the Crouzon group versus the control (P = 0.04). Conclusions Three-dimensional analysis revealed notably decreased pharyngeal and nasal airway volumes in patients with Crouzon syndrome, but nasal bone tissue and soft tissue measurements showed very little change between patients and control subjects.
A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer.
Kansra, Vikram, Wilcoxen, Keith, McClure, Ty, Martell, Robert E., Agarwal, Shefali , Kurzrock, Razelle , Galanis, Evanthia , Johnson, Derek R.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2092-2092

10.1200/jco.2014.32.15_suppl.2092 Get It